• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用erenumab治疗慢性偏头痛女性的经期头痛:一项观察性病例系列研究

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series.

作者信息

Ornello Raffaele, Frattale Ilaria, Caponnetto Valeria, De Matteis Eleonora, Pistoia Francesca, Sacco Simona

机构信息

Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, 67100 L'Aquila, Italy.

Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, 00133 Rome, Italy.

出版信息

Brain Sci. 2021 Mar 13;11(3):370. doi: 10.3390/brainsci11030370.

DOI:10.3390/brainsci11030370
PMID:33805838
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8000210/
Abstract

BACKGROUND

We aimed to assess the differences between menstrual and non-menstrual headache in women with chronic migraine treated with erenumab.

METHODS

We included fertile women from a single center. Patients were defined as responders to erenumab if reporting a ≥50% decrease in monthly headache days, as compared to pre-treatment for more than half of the treatment period. Premenstrual days were defined as the two days preceding menstruation, while menstrual days were defined as the first three days of menstruation.

RESULTS

We included 18 women (11 erenumab responders and 7 erenumab non-responders) contributing to a total of 103 menstrual cycles and 2926 days. The proportion of headache days was higher in menstrual than in premenstrual and non-menstrual days in erenumab responders (34.4% vs. 14.8% vs. 16.3%, respectively; < 0.001) and in erenumab non-responders (71.4% vs. 53.6% vs. 48.3%, respectively; < 0.001). Headache days with ≥2 acute medications were higher in menstrual than in premenstrual or non-menstrual headache days in erenumab non-responders ( = 0.002) but not in erenumab responders ( = 0.620).

CONCLUSIONS

Our data suggest that migraine is more frequent during than outside menstrual days even in women treated with erenumab.

摘要

背景

我们旨在评估接受erenumab治疗的慢性偏头痛女性月经性头痛和非月经性头痛之间的差异。

方法

我们纳入了来自单一中心的育龄女性。如果患者报告在超过一半的治疗期内每月头痛天数较治疗前减少≥50%,则被定义为erenumab应答者。经前期被定义为月经前的两天,而月经期被定义为月经的前三天。

结果

我们纳入了18名女性(11名erenumab应答者和7名erenumab无应答者),共涉及103个月经周期和2926天。在erenumab应答者中,月经期的头痛天数比例高于经前期和非月经期(分别为34.4%、14.8%和16.3%;<0.001),在erenumab无应答者中也是如此(分别为71.4%、53.6%和48.3%;<0.001)。在erenumab无应答者中,使用≥2种急性药物的头痛天数在月经期高于经前期或非月经期(P=0.002),但在erenumab应答者中并非如此(P=0.620)。

结论

我们的数据表明,即使在接受erenumab治疗的女性中,偏头痛在月经期比非月经期更频繁。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9322/8000210/cc1622ee8e3e/brainsci-11-00370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9322/8000210/cc1622ee8e3e/brainsci-11-00370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9322/8000210/cc1622ee8e3e/brainsci-11-00370-g001.jpg

相似文献

1
Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series.用erenumab治疗慢性偏头痛女性的经期头痛:一项观察性病例系列研究
Brain Sci. 2021 Mar 13;11(3):370. doi: 10.3390/brainsci11030370.
2
Efficacy and safety of erenumab in women with a history of menstrual migraine.依瑞奈尤单抗治疗有经期偏头痛病史女性的疗效和安全性。
J Headache Pain. 2020 Aug 3;21(1):95. doi: 10.1186/s10194-020-01167-6.
3
Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.真实世界研究:魁北克省(加拿大东部)难治性偏头痛患者接受依瑞奈尤单抗治疗的系列病例。
Clin Drug Investig. 2021 Aug;41(8):733-739. doi: 10.1007/s40261-021-01059-w. Epub 2021 Jul 21.
4
Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.偏头痛患者中对CGRP配体抗体治疗无反应者改用erenumab的效果:一项真实世界队列研究。
Front Neurol. 2023 Mar 22;14:1154420. doi: 10.3389/fneur.2023.1154420. eCollection 2023.
5
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab.偏头痛患者治疗前后的功能连接和疼痛诱导脑激活的纵向变化:依瑞奈玛单抗的功能 MRI 研究。
J Headache Pain. 2022 Dec 14;23(1):159. doi: 10.1186/s10194-022-01526-5.
6
Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine.导水管周围灰质和扣带回前部铁沉积的纵向差异与依瑞奈尤单抗治疗偏头痛的反应相关。
Cephalalgia. 2023 Feb;43(2):3331024221144783. doi: 10.1177/03331024221144783.
7
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.依瑞奈玛单抗预防慢性偏头痛的安全性和疗效:一项随机、双盲、安慰剂对照的 2 期临床试验。
Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28.
8
Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine.erenumab可减少与头痛相关的病假天数和医疗就诊次数:一项针对偏头痛在职患者的回顾性真实世界研究。
Neurol Ther. 2022 Mar;11(1):223-235. doi: 10.1007/s40120-021-00303-x. Epub 2021 Dec 10.
9
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study.依瑞奈尤单抗治疗既往使用五种一线口服预防性药物及A型肉毒毒素治疗失败的慢性偏头痛患者:一项双中心回顾性观察研究。
Front Neurol. 2020 May 28;11:417. doi: 10.3389/fneur.2020.00417. eCollection 2020.
10
Erenumab in Chronic Migraine: An Australian Experience.依瑞奈尤单抗治疗慢性偏头痛:澳大利亚经验。
Headache. 2020 Nov;60(10):2555-2562. doi: 10.1111/head.13968. Epub 2020 Sep 29.

引用本文的文献

1
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response.抗降钙素基因相关肽单克隆抗体的范围综述与荟萃分析:预测反应
Pharmaceuticals (Basel). 2023 Jun 27;16(7):934. doi: 10.3390/ph16070934.
2
Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study.女性偏头痛患者的性激素和降钙素基因相关肽:一项横断面、匹配队列研究。
Neurology. 2023 Apr 25;100(17):e1825-e1835. doi: 10.1212/WNL.0000000000207114. Epub 2023 Feb 22.
3
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data.

本文引用的文献

1
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.依瑞奈玛单抗治疗患者中慢性偏头痛向发作性偏头痛的转换:来自意大利某地区的真实世界数据。
J Headache Pain. 2020 Aug 15;21(1):102. doi: 10.1186/s10194-020-01171-w.
2
Efficacy and safety of erenumab in women with a history of menstrual migraine.依瑞奈尤单抗治疗有经期偏头痛病史女性的疗效和安全性。
J Headache Pain. 2020 Aug 3;21(1):95. doi: 10.1186/s10194-020-01167-6.
3
A Pre-Existing Myogenic Temporomandibular Disorder Increases Trigeminal Calcitonin Gene-Related Peptide and Enhances Nitroglycerin-Induced Hypersensitivity in Mice.
降钙素基因相关肽单克隆抗体治疗偏头痛预防:真实世界数据的系统评价。
Cells. 2022 Dec 29;12(1):143. doi: 10.3390/cells12010143.
4
The ultimate guide to the anti-CGRP monoclonal antibodies galaxy.抗 CGRP 单克隆抗体的终极指南。
Neurol Sci. 2022 Sep;43(9):5673-5685. doi: 10.1007/s10072-022-06199-1. Epub 2022 Jun 20.
5
Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.erenumab预防偏头痛:聚焦患者选择、观点与结果。
Ther Clin Risk Manag. 2022 Apr 5;18:359-378. doi: 10.2147/TCRM.S263825. eCollection 2022.
6
Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP.偏头痛中的激素影响——雌激素、催产素和 CGRP 的相互作用。
Nat Rev Neurol. 2021 Oct;17(10):621-633. doi: 10.1038/s41582-021-00544-2. Epub 2021 Sep 20.
7
Acute and Preventive Management of Migraine during Menstruation and Menopause.月经和绝经期间偏头痛的急性及预防性管理
J Clin Med. 2021 May 24;10(11):2263. doi: 10.3390/jcm10112263.
预先存在的肌源性颞下颌关节紊乱症增加了小鼠三叉神经降钙素基因相关肽,并增强了硝酸甘油诱导的敏感性。
Int J Mol Sci. 2020 Jun 5;21(11):4049. doi: 10.3390/ijms21114049.
4
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.靶向降钙素基因相关肽治疗偏头痛:作用机制、抗体、小分子药物及展望
Expert Rev Neurother. 2020 Jun;20(6):627-641. doi: 10.1080/14737175.2020.1772758. Epub 2020 Jun 2.
5
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.意大利中部阿布鲁佐地区依瑞奈umab 的疗效和安全性的真实数据。
J Headache Pain. 2020 Apr 7;21(1):32. doi: 10.1186/s10194-020-01102-9.
6
Gut-brain Axis and migraine headache: a comprehensive review.肠-脑轴与偏头痛:全面综述。
J Headache Pain. 2020 Feb 13;21(1):15. doi: 10.1186/s10194-020-1078-9.
7
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.多次预防治疗失败后预防偏头痛使用依瑞奈玛的适当剂量:批判性评价。
J Headache Pain. 2019 Oct 30;20(1):99. doi: 10.1186/s10194-019-1054-4.
8
Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications.理解偏头痛中精神共病的性质:一项侧重于相互作用和治疗意义的系统综述。
J Headache Pain. 2019 May 9;20(1):51. doi: 10.1186/s10194-019-0988-x.
9
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.欧洲头痛联合会关于使用作用于降钙素基因相关肽或其受体的单克隆抗体预防偏头痛的指南。
J Headache Pain. 2019 Jan 16;20(1):6. doi: 10.1186/s10194-018-0955-y.
10
Male and female sex hormones in primary headaches.原发性头痛中的男女性激素。
J Headache Pain. 2018 Nov 29;19(1):117. doi: 10.1186/s10194-018-0922-7.